{"title":"Verquvo","description":null,"products":[{"product_id":"verquvo-vericiguat","title":"Verquvo (Vericiguat)","description":"\u003cdiv class=\"flex-1 overflow-hidden @container\/thread translate-y-[2rem] -mt-[2rem] pb-[1.5rem]\"\u003e\r\n\u003cdiv class=\"flex h-full flex-col overflow-y-auto\"\u003e\r\n\u003cdiv class=\"flex flex-col text-sm md:pb-9\"\u003e\r\n\u003carticle class=\"w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-49\" data-scroll-anchor=\"true\"\u003e\r\n\u003cdiv class=\"m-auto text-base py-[18px] px-6\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn @xs\/thread:px-0 @sm\/thread:px-1.5 @md\/thread:px-4\"\u003e\r\n\u003cdiv class=\"flex-col gap-1 md:gap-3\"\u003e\r\n\u003cdiv class=\"flex max-w-full flex-col flex-grow\"\u003e\r\n\u003cdiv class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+\u0026amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"2d806202-b9ff-4755-979c-5e5c5601c787\" data-message-model-slug=\"o3-mini\"\u003e\r\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\"\u003e\r\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\r\n\u003ch3 data-start=\"358\" data-end=\"383\"\u003eWhat is Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"384\" data-end=\"868\"\u003e\u003cstrong data-start=\"384\" data-end=\"398\"\u003eVericiguat\u003c\/strong\u003e is an oral soluble guanylate cyclase (sGC) stimulator used in the management of chronic heart failure with reduced ejection fraction (HFrEF), particularly in patients who have recently experienced worsening heart failure events. It is marketed under the brand name \u003cstrong data-start=\"664\" data-end=\"675\"\u003eVerquvo\u003c\/strong\u003e and is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.\u003cbr data-start=\"770\" data-end=\"773\"\u003e\u003cem data-start=\"773\" data-end=\"868\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"785\" data-end=\"867\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"870\" data-end=\"873\"\u003e\r\n\u003ch3 data-start=\"875\" data-end=\"929\"\u003eWhat are the other popular names for Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"930\" data-end=\"1155\"\u003eVericiguat is primarily known by its brand name \u003cstrong data-start=\"978\" data-end=\"989\"\u003eVerquvo\u003c\/strong\u003e. In clinical and academic literature, it is also referred to by its generic name, vericiguat.\u003cbr data-start=\"1083\" data-end=\"1086\"\u003e\u003cem data-start=\"1086\" data-end=\"1155\"\u003eReference: \u003ca href=\"https:\/\/www.drugs.com\/\" target=\"_new\" rel=\"noopener\" data-start=\"1098\" data-end=\"1154\"\u003eDrugs.com: Vericiguat Overview\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1157\" data-end=\"1160\"\u003e\r\n\u003ch3 data-start=\"1162\" data-end=\"1214\"\u003eWhat is the drug classification of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1215\" data-end=\"1535\"\u003eVericiguat is classified as an \u003cstrong data-start=\"1246\" data-end=\"1297\"\u003eoral soluble guanylate cyclase (sGC) stimulator\u003c\/strong\u003e. It falls under the broader category of \u003cstrong data-start=\"1338\" data-end=\"1367\"\u003eheart failure medications\u003c\/strong\u003e and is specifically designated for use as an adjunct therapy in patients with chronic HFrEF.\u003cbr data-start=\"1460\" data-end=\"1463\"\u003e\u003cem data-start=\"1463\" data-end=\"1535\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"1475\" data-end=\"1534\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1537\" data-end=\"1540\"\u003e\r\n\u003ch3 data-start=\"1542\" data-end=\"1589\"\u003eWhat is the mode of action of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1590\" data-end=\"2149\"\u003eVericiguat works by both sensitizing soluble guanylate cyclase (sGC) to endogenous nitric oxide (NO) and directly stimulating sGC independent of NO. This dual mechanism leads to increased production of cyclic guanosine monophosphate (cGMP), which promotes vasodilation, reduces myocardial stress, and exerts anti‑remodeling effects on the heart. These actions collectively help reduce cardiac workload and improve cardiovascular outcomes in patients with HFrEF.\u003cbr data-start=\"2051\" data-end=\"2054\"\u003e\u003cem data-start=\"2054\" data-end=\"2149\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2066\" data-end=\"2148\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2151\" data-end=\"2154\"\u003e\r\n\u003ch3 data-start=\"2156\" data-end=\"2185\"\u003eHow is Vericiguat used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2186\" data-end=\"2693\"\u003eVericiguat is used as part of a comprehensive treatment plan for adult patients with chronic HFrEF who have had a recent episode of worsening heart failure (e.g., hospitalization or need for outpatient intravenous diuretics). It is prescribed in addition to standard heart failure therapy (such as beta‑blockers, ACE inhibitors, or ARBs) to further reduce the risk of adverse cardiovascular events.\u003cbr data-start=\"2584\" data-end=\"2587\"\u003e\u003cem data-start=\"2587\" data-end=\"2693\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2599\" data-end=\"2692\"\u003ePARADIGM-HF and VICTORIA Trials – NEJM\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2695\" data-end=\"2698\"\u003e\r\n\u003ch3 data-start=\"2700\" data-end=\"2771\"\u003eWhat is the recommended dosage and administration for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"2772\" data-end=\"3226\"\u003e\r\n\u003cli data-start=\"2772\" data-end=\"2972\"\u003e\n\u003cstrong data-start=\"2774\" data-end=\"2784\"\u003eDosage\u003c\/strong\u003e: The recommended starting dose is \u003cstrong data-start=\"2819\" data-end=\"2840\"\u003e2.5 mg once daily\u003c\/strong\u003e, which is gradually titrated upward (typically to 5 mg, then 10 mg, and ultimately 15 mg once daily) as tolerated by the patient.\u003c\/li\u003e\r\n\u003cli data-start=\"2973\" data-end=\"3226\"\u003e\n\u003cstrong data-start=\"2975\" data-end=\"2993\"\u003eAdministration\u003c\/strong\u003e: Vericiguat is taken orally in capsule form and may be taken with or without food. Consistent daily dosing is crucial for maintaining its therapeutic effect.\u003cbr data-start=\"3151\" data-end=\"3154\"\u003e\u003cem data-start=\"3154\" data-end=\"3226\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"3166\" data-end=\"3225\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3228\" data-end=\"3231\"\u003e\r\n\u003ch3 data-start=\"3233\" data-end=\"3296\"\u003eWhat prescribing information is important for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3297\" data-end=\"3896\"\u003e\r\n\u003cli data-start=\"3297\" data-end=\"3482\"\u003e\n\u003cstrong data-start=\"3299\" data-end=\"3314\"\u003eIndications\u003c\/strong\u003e: Vericiguat is indicated for patients with chronic heart failure with reduced ejection fraction (HFrEF) who have recently experienced worsening heart failure events.\u003c\/li\u003e\r\n\u003cli data-start=\"3483\" data-end=\"3689\"\u003e\n\u003cstrong data-start=\"3485\" data-end=\"3506\"\u003eContraindications\u003c\/strong\u003e: It is contraindicated in patients with a history of angioedema related to ACE inhibitor or ARB therapy and should not be coadministered with nitrates or other potent vasodilators.\u003c\/li\u003e\r\n\u003cli data-start=\"3690\" data-end=\"3896\"\u003e\n\u003cstrong data-start=\"3692\" data-end=\"3706\"\u003eMonitoring\u003c\/strong\u003e: Patients should have regular assessments of blood pressure, renal function, electrolytes, and signs of infection.\u003cbr data-start=\"3821\" data-end=\"3824\"\u003e\u003cem data-start=\"3824\" data-end=\"3896\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"3836\" data-end=\"3895\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3898\" data-end=\"3901\"\u003e\r\n\u003ch3 data-start=\"3903\" data-end=\"3988\"\u003eWhat safety information, warnings, and cautions are associated with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3989\" data-end=\"4940\"\u003e\r\n\u003cli data-start=\"3989\" data-end=\"4096\"\u003e\n\u003cstrong data-start=\"3991\" data-end=\"4014\"\u003eCommon Side Effects\u003c\/strong\u003e: These include hypotension, dizziness, anemia, and gastrointestinal discomfort.\u003c\/li\u003e\r\n\u003cli data-start=\"4097\" data-end=\"4940\"\u003e\n\u003cstrong data-start=\"4099\" data-end=\"4122\"\u003eWarnings \u0026amp; Cautions\u003c\/strong\u003e:\r\n\u003cul data-start=\"4128\" data-end=\"4940\"\u003e\r\n\u003cli data-start=\"4128\" data-end=\"4243\"\u003e\n\u003cstrong data-start=\"4130\" data-end=\"4145\"\u003eHypotension\u003c\/strong\u003e: Vericiguat can cause a significant drop in blood pressure, particularly during dose titration.\u003c\/li\u003e\r\n\u003cli data-start=\"4246\" data-end=\"4378\"\u003e\n\u003cstrong data-start=\"4248\" data-end=\"4266\"\u003eInfection Risk\u003c\/strong\u003e: Although not as immunosuppressive as some other agents, patients should be monitored for signs of infection.\u003c\/li\u003e\r\n\u003cli data-start=\"4381\" data-end=\"4650\"\u003e\n\u003cstrong data-start=\"4383\" data-end=\"4404\"\u003eDrug Interactions\u003c\/strong\u003e:\r\n\u003cul data-start=\"4412\" data-end=\"4650\"\u003e\r\n\u003cli data-start=\"4412\" data-end=\"4525\"\u003e\n\u003cstrong data-start=\"4414\" data-end=\"4446\"\u003eNitrates and PDE5 Inhibitors\u003c\/strong\u003e: Concomitant use is contraindicated due to the risk of profound hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"4530\" data-end=\"4650\"\u003e\n\u003cstrong data-start=\"4532\" data-end=\"4559\"\u003eOther Antihypertensives\u003c\/strong\u003e: Combined use may amplify blood pressure–lowering effects, requiring careful monitoring.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4653\" data-end=\"4940\"\u003e\n\u003cstrong data-start=\"4655\" data-end=\"4687\"\u003eRenal and Hepatic Impairment\u003c\/strong\u003e: Dose adjustments and frequent monitoring may be necessary in patients with impaired renal or hepatic function.\u003cbr data-start=\"4799\" data-end=\"4802\"\u003e\u003cem data-start=\"4802\" data-end=\"4940\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"4814\" data-end=\"4896\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e, \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"4898\" data-end=\"4939\"\u003eFDA Verquvo Label\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"4942\" data-end=\"4945\"\u003e\r\n\u003ch3 data-start=\"4947\" data-end=\"5024\"\u003eWhat additional drug interactions should be considered with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"5025\" data-end=\"5605\"\u003e\r\n\u003cli data-start=\"5025\" data-end=\"5203\"\u003e\n\u003cstrong data-start=\"5027\" data-end=\"5098\"\u003eNitrates and Phosphodiesterase Type 5 Inhibitors (e.g., sildenafil)\u003c\/strong\u003e: Their combined use with Vericiguat is contraindicated due to an increased risk of severe hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"5204\" data-end=\"5303\"\u003e\n\u003cstrong data-start=\"5206\" data-end=\"5239\"\u003eOther Antihypertensive Agents\u003c\/strong\u003e: Coadministration may result in additive hypotensive effects.\u003c\/li\u003e\r\n\u003cli data-start=\"5304\" data-end=\"5605\"\u003e\n\u003cstrong data-start=\"5306\" data-end=\"5334\"\u003eCYP450 Enzyme Modulators\u003c\/strong\u003e: Although Vericiguat is not predominantly metabolized by CYP enzymes, caution is advised when it is used with drugs that significantly alter blood pressure or fluid balance.\u003cbr data-start=\"5508\" data-end=\"5511\"\u003e\u003cem data-start=\"5511\" data-end=\"5605\"\u003eReference: \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5523\" data-end=\"5604\"\u003eClinical Pharmacology Reviews, ACR Guidelines\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"5607\" data-end=\"5610\"\u003e\r\n\u003ch3 data-start=\"5612\" data-end=\"5684\"\u003eWhere can I learn more about Vericiguat and its clinical evidence?\u003c\/h3\u003e\r\n\u003cp data-start=\"5685\" data-end=\"5803\"\u003eFor further details on clinical studies, dosing strategies, and safety monitoring, refer to the following resources:\u003c\/p\u003e\r\n\u003cul data-start=\"5804\" data-end=\"6171\"\u003e\r\n\u003cli data-start=\"5804\" data-end=\"5871\"\u003e\u003cstrong data-start=\"5806\" data-end=\"5869\"\u003e\u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5808\" data-end=\"5867\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5872\" data-end=\"5979\"\u003e\u003cstrong data-start=\"5874\" data-end=\"5977\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"5876\" data-end=\"5975\"\u003eArmstrong et al., NEJM 2020 – VICTORIA Trial\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5980\" data-end=\"6099\"\u003e\n\u003cstrong data-start=\"5982\" data-end=\"6028\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5984\" data-end=\"6026\"\u003ePubMed\u003c\/a\u003e\u003c\/strong\u003e for additional peer‑reviewed research on vericiguat in heart failure\u003c\/li\u003e\r\n\u003cli data-start=\"6100\" data-end=\"6171\"\u003e\u003cstrong data-start=\"6102\" data-end=\"6171\"\u003e\u003ca href=\"https:\/\/www.acc.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6104\" data-end=\"6169\"\u003eAmerican College of Cardiology Guidelines\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6173\" data-end=\"6176\"\u003e\r\n\u003ch3 data-start=\"6178\" data-end=\"6198\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6199\" data-end=\"7031\"\u003e\u003cstrong data-start=\"6199\" data-end=\"6223\"\u003eVericiguat (Verquvo)\u003c\/strong\u003e is an innovative, orally administered sGC stimulator that significantly improves outcomes in patients with chronic heart failure with reduced ejection fraction (HFrEF) who have experienced recent worsening heart failure events. By enhancing cGMP production, vericiguat promotes vasodilation and reduces cardiac stress, contributing to a decrease in cardiovascular events. However, due to its potent blood pressure–lowering effects and potential drug interactions (especially with nitrates and other vasodilators), it must be used with caution and under strict medical supervision.\u003cbr data-start=\"6804\" data-end=\"6807\"\u003e\u003cem data-start=\"6807\" data-end=\"7031\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"pr-2 lg:pr-0\"\u003e \u003c\/div\u003e\r\n\u003cdiv class=\"mt-3 w-full empty:hidden\"\u003e\r\n\u003cdiv class=\"text-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"absolute\"\u003e\r\n\u003cdiv class=\"flex items-center justify-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/article\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"md:pt-0 dark:border-white\/20 md:border-transparent md:dark:border-transparent w-full isolate has-[[data-has-thread-error]]:[box-shadow:var(--sharp-edge-bottom-shadow)] has-[[data-has-thread-error]]:pt-2\"\u003e\r\n\u003cdiv\u003e\r\n\u003cdiv class=\"m-auto text-base px-3 md:px-4 w-full md:px-5 lg:px-4 xl:px-5\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"flex justify-center empty:hidden\"\u003e \u003c\/div\u003e\r\n\u003cform class=\"w-full\" aria-haspopup=\"dialog\" aria-expanded=\"false\" aria-controls=\"radix-:r19a:\" data-state=\"closed\"\u003e\r\n\u003cdiv class=\"relative z-[1] flex h-full max-w-full flex-1 flex-col\"\u003e\r\n\u003cdiv class=\"absolute bottom-full left-0 right-0 z-20\"\u003e \u003c\/div\u003e\r\n\u003cdiv class=\"group relative z-[1] flex w-full items-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/form\u003e\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Magento","offers":[{"title":"2.5 mg","offer_id":49210174931190,"sku":"Verquvo- 2.5 mg","price":142.86,"currency_code":"USD","in_stock":true},{"title":"false","offer_id":49210174963958,"sku":"Verquvo-5mg","price":142.86,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":49210174996726,"sku":"Verquvo-10mg","price":142.9,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0756\/1855\/0006\/files\/untitled_design_59.png?v=1760863810"},{"product_id":"verquvo-vericiguat-1","title":"Verquvo (Vericiguat)","description":"\u003ch3 data-start=\"231\" data-end=\"256\"\u003eWhat is Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"257\" data-end=\"596\"\u003e\u003cstrong data-start=\"257\" data-end=\"271\"\u003eVericiguat\u003c\/strong\u003e is an oral medication used as an adjunct to standard therapy in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) who remain at high risk of cardiovascular death or heart failure hospitalization. It is designed to improve cardiac performance by enhancing the nitric oxide–sGC–cGMP pathway.\u003c\/p\u003e\r\n\u003cp data-start=\"598\" data-end=\"735\"\u003e\u003cem data-start=\"598\" data-end=\"735\"\u003eReference: U.S. Food and Drug Administration (FDA) vericiguat prescribing information; ClinicalTrials.gov (VICTORIA trial, NCT02861534)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"737\" data-end=\"740\"\u003e\r\n\u003ch3 data-start=\"742\" data-end=\"796\"\u003eWhat are the other popular names for Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"797\" data-end=\"955\"\u003eVericiguat is marketed under the brand name \u003cstrong data-start=\"841\" data-end=\"852\"\u003eVerquvo\u003c\/strong\u003e. In clinical practice and academic literature, it is also referred to by its generic name, vericiguat.\u003c\/p\u003e\r\n\u003cp data-start=\"957\" data-end=\"998\"\u003e\u003cem data-start=\"957\" data-end=\"998\"\u003eReference: U.S. FDA; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1000\" data-end=\"1003\"\u003e\r\n\u003ch3 data-start=\"1005\" data-end=\"1057\"\u003eWhat is the drug classification of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1058\" data-end=\"1263\"\u003eVericiguat is classified as an \u003cstrong data-start=\"1089\" data-end=\"1140\"\u003eoral soluble guanylate cyclase (sGC) stimulator\u003c\/strong\u003e. It falls under the therapeutic category of \u003cstrong data-start=\"1185\" data-end=\"1214\"\u003eheart failure medications\u003c\/strong\u003e, specifically indicated for patients with HFrEF.\u003c\/p\u003e\r\n\u003cp data-start=\"1265\" data-end=\"1368\"\u003e\u003cem data-start=\"1265\" data-end=\"1368\"\u003eReference: U.S. FDA; National Institutes of Health (NIH); American Heart Association (AHA) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1370\" data-end=\"1373\"\u003e\r\n\u003ch3 data-start=\"1375\" data-end=\"1422\"\u003eWhat is the mode of action of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1423\" data-end=\"1669\"\u003eVericiguat works by enhancing the sensitivity of soluble guanylate cyclase (sGC) to endogenous nitric oxide (NO) and by directly stimulating sGC. This dual mechanism increases the production of cyclic guanosine monophosphate (cGMP), leading to:\u003c\/p\u003e\r\n\u003cul data-start=\"1670\" data-end=\"2006\"\u003e\r\n\u003cli data-start=\"1670\" data-end=\"1747\"\u003e\n\u003cstrong data-start=\"1672\" data-end=\"1689\"\u003eVasodilation:\u003c\/strong\u003e Relaxation of vascular smooth muscle reduces afterload.\u003c\/li\u003e\r\n\u003cli data-start=\"1748\" data-end=\"1891\"\u003e\n\u003cstrong data-start=\"1750\" data-end=\"1782\"\u003eImproved Cardiac Efficiency:\u003c\/strong\u003e Lower resistance allows the heart to pump more effectively without significantly increasing oxygen demand.\u003c\/li\u003e\r\n\u003cli data-start=\"1892\" data-end=\"2006\"\u003e\n\u003cstrong data-start=\"1894\" data-end=\"1925\"\u003eReduced Cardiac Remodeling:\u003c\/strong\u003e Over time, these effects may help limit adverse structural changes in the heart.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2008\" data-end=\"2102\"\u003e\u003cem data-start=\"2008\" data-end=\"2102\"\u003eReference: New England Journal of Medicine (NEJM) – VICTORIA trial (NEJMoa1917589); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2104\" data-end=\"2107\"\u003e\r\n\u003ch3 data-start=\"2109\" data-end=\"2138\"\u003eHow is Vericiguat used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2139\" data-end=\"2432\"\u003eVericiguat is used as an adjunct to guideline‑directed medical therapy (GDMT) in patients with symptomatic chronic HFrEF. It is prescribed for patients who continue to experience symptoms despite treatment with beta‑blockers, ACE inhibitors or ARBs, and mineralocorticoid receptor antagonists.\u003c\/p\u003e\r\n\u003cp data-start=\"2434\" data-end=\"2527\"\u003e\u003cem data-start=\"2434\" data-end=\"2527\"\u003eReference: American Heart Association (AHA) guidelines; ClinicalTrials.gov (VICTORIA trial)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2529\" data-end=\"2532\"\u003e\r\n\u003ch3 data-start=\"2534\" data-end=\"2605\"\u003eWhat is the recommended dosage and administration for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"2606\" data-end=\"3062\"\u003e\r\n\u003cli data-start=\"2606\" data-end=\"2855\"\u003e\n\u003cstrong data-start=\"2608\" data-end=\"2619\"\u003eDosage:\u003c\/strong\u003e\r\n\u003cul data-start=\"2624\" data-end=\"2855\"\u003e\r\n\u003cli data-start=\"2624\" data-end=\"2855\"\u003eTreatment typically begins with a lower dose (for example, \u003cstrong data-start=\"2685\" data-end=\"2706\"\u003e2.5 mg once daily\u003c\/strong\u003e) with gradual up-titration to a target maintenance dose (commonly between 10 mg and 15 mg once daily) based on clinical response and tolerability.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"2856\" data-end=\"3062\"\u003e\n\u003cstrong data-start=\"2858\" data-end=\"2877\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2882\" data-end=\"3062\"\u003e\r\n\u003cli data-start=\"2882\" data-end=\"3062\"\u003eVericiguat is taken orally in capsule form. It may be taken with or without food, but consistent dosing at the same time each day is advised for maintaining steady plasma levels.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3064\" data-end=\"3170\"\u003e\u003cem data-start=\"3064\" data-end=\"3170\"\u003eReference: U.S. FDA vericiguat prescribing information; ClinicalTrials.gov (VICTORIA trial, NCT02861534)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3172\" data-end=\"3175\"\u003e\r\n\u003ch3 data-start=\"3177\" data-end=\"3240\"\u003eWhat prescribing information is important for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3241\" data-end=\"4071\"\u003e\r\n\u003cli data-start=\"3241\" data-end=\"3451\"\u003e\n\u003cstrong data-start=\"3243\" data-end=\"3259\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3264\" data-end=\"3451\"\u003e\r\n\u003cli data-start=\"3264\" data-end=\"3451\"\u003eVericiguat is indicated to reduce the risk of cardiovascular death and heart failure hospitalization in patients with chronic HFrEF who are at high risk despite optimal medical therapy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3452\" data-end=\"3742\"\u003e\n\u003cstrong data-start=\"3454\" data-end=\"3476\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3481\" data-end=\"3742\"\u003e\r\n\u003cli data-start=\"3481\" data-end=\"3597\"\u003eIt is contraindicated in patients with a known hypersensitivity to vericiguat or any component of the formulation.\u003c\/li\u003e\r\n\u003cli data-start=\"3600\" data-end=\"3742\"\u003eConcomitant use with nitrates or potent phosphodiesterase type 5 (PDE5) inhibitors is contraindicated due to the risk of severe hypotension.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3743\" data-end=\"3865\"\u003e\n\u003cstrong data-start=\"3745\" data-end=\"3760\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3765\" data-end=\"3865\"\u003e\r\n\u003cli data-start=\"3765\" data-end=\"3865\"\u003ePatients should be regularly monitored for blood pressure, renal function, and serum electrolytes.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3866\" data-end=\"4071\"\u003e\n\u003cstrong data-start=\"3868\" data-end=\"3895\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3900\" data-end=\"4071\"\u003e\r\n\u003cli data-start=\"3900\" data-end=\"4071\"\u003eVericiguat is not recommended during pregnancy. Women of childbearing potential must use effective contraception during treatment and for a period after discontinuation.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4073\" data-end=\"4199\"\u003e\u003cem data-start=\"4073\" data-end=\"4199\"\u003eReference: U.S. Food and Drug Administration (FDA) vericiguat label; National Institutes of Health (NIH) clinical guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4201\" data-end=\"4204\"\u003e\r\n\u003ch3 data-start=\"4206\" data-end=\"4291\"\u003eWhat safety information, warnings, and cautions are associated with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"4292\" data-end=\"5016\"\u003e\r\n\u003cli data-start=\"4292\" data-end=\"4370\"\u003e\n\u003cstrong data-start=\"4294\" data-end=\"4318\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4323\" data-end=\"4370\"\u003e\r\n\u003cli data-start=\"4323\" data-end=\"4370\"\u003eHypotension, dizziness, headache, and anemia.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4371\" data-end=\"5016\"\u003e\n\u003cstrong data-start=\"4373\" data-end=\"4397\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4402\" data-end=\"5016\"\u003e\r\n\u003cli data-start=\"4402\" data-end=\"4566\"\u003e\n\u003cstrong data-start=\"4404\" data-end=\"4420\"\u003eHypotension:\u003c\/strong\u003e Patients are at risk for low blood pressure, especially during dose titration. Advise slow position changes and monitor blood pressure closely.\u003c\/li\u003e\r\n\u003cli data-start=\"4569\" data-end=\"4632\"\u003e\n\u003cstrong data-start=\"4571\" data-end=\"4586\"\u003eFetal Harm:\u003c\/strong\u003e Vericiguat is contraindicated in pregnancy.\u003c\/li\u003e\r\n\u003cli data-start=\"4635\" data-end=\"4858\"\u003e\n\u003cstrong data-start=\"4637\" data-end=\"4659\"\u003eDrug Interactions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4666\" data-end=\"4858\"\u003e\r\n\u003cli data-start=\"4666\" data-end=\"4750\"\u003eConcomitant use with nitrates or PDE5 inhibitors may lead to severe hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"4755\" data-end=\"4858\"\u003eCoadministration with other antihypertensives may result in additive blood pressure–lowering effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4861\" data-end=\"5016\"\u003e\n\u003cstrong data-start=\"4863\" data-end=\"4882\"\u003eOrgan Function:\u003c\/strong\u003e Caution is advised in patients with impaired renal or hepatic function; these patients require dose adjustments and close monitoring.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5018\" data-end=\"5141\"\u003e\u003cem data-start=\"5018\" data-end=\"5141\"\u003eReference: U.S. FDA; New England Journal of Medicine (NEJM) – VICTORIA trial; American Heart Association (AHA) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5143\" data-end=\"5146\"\u003e\r\n\u003ch3 data-start=\"5148\" data-end=\"5214\"\u003eWhat drug interactions should be considered with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"5215\" data-end=\"5679\"\u003e\r\n\u003cli data-start=\"5215\" data-end=\"5383\"\u003e\n\u003cstrong data-start=\"5217\" data-end=\"5280\"\u003eNitrates and PDE5 Inhibitors (e.g., Sildenafil, Tadalafil):\u003c\/strong\u003e\r\n\u003cul data-start=\"5285\" data-end=\"5383\"\u003e\r\n\u003cli data-start=\"5285\" data-end=\"5383\"\u003eThese are contraindicated when used with vericiguat because of the risk of profound hypotension.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5384\" data-end=\"5521\"\u003e\n\u003cstrong data-start=\"5386\" data-end=\"5420\"\u003eOther Antihypertensive Agents:\u003c\/strong\u003e\r\n\u003cul data-start=\"5425\" data-end=\"5521\"\u003e\r\n\u003cli data-start=\"5425\" data-end=\"5521\"\u003eConcurrent use may enhance blood pressure–lowering effects and necessitate dosage adjustments.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5522\" data-end=\"5679\"\u003e\n\u003cstrong data-start=\"5524\" data-end=\"5560\"\u003eAgents Affecting Renal Function:\u003c\/strong\u003e\r\n\u003cul data-start=\"5565\" data-end=\"5679\"\u003e\r\n\u003cli data-start=\"5565\" data-end=\"5679\"\u003eDrugs that impair renal hemodynamics may affect the pharmacokinetics of vericiguat; close monitoring is advised.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5681\" data-end=\"5760\"\u003e\u003cem data-start=\"5681\" data-end=\"5760\"\u003eReference: U.S. FDA vericiguat label; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5762\" data-end=\"5765\"\u003e\r\n\u003ch3 data-start=\"5767\" data-end=\"5861\"\u003eWhere can I find additional clinical evidence and detailed information about Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"5862\" data-end=\"5956\"\u003eFor further details on clinical studies, dosing guidelines, and safety monitoring, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"5957\" data-end=\"6378\"\u003e\r\n\u003cli data-start=\"5957\" data-end=\"6045\"\u003e\n\u003cstrong data-start=\"5959\" data-end=\"6011\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6012\" data-end=\"6043\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6046\" data-end=\"6154\"\u003e\n\u003cstrong data-start=\"6048\" data-end=\"6102\"\u003eClinicalTrials.gov – VICTORIA Trial (NCT02861534):\u003c\/strong\u003e \u003ca href=\"https:\/\/clinicaltrials.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6103\" data-end=\"6152\"\u003eClinicalTrials.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6155\" data-end=\"6291\"\u003e\n\u003cstrong data-start=\"6157\" data-end=\"6229\"\u003eNew England Journal of Medicine (NEJM) – VICTORIA Trial Publication:\u003c\/strong\u003e \u003ca target=\"_new\" rel=\"noopener\" data-start=\"6230\" data-end=\"6289\"\u003eNEJM\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6292\" data-end=\"6378\"\u003e\n\u003cstrong data-start=\"6294\" data-end=\"6342\"\u003eAmerican Heart Association (AHA) Guidelines:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.heart.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6343\" data-end=\"6378\"\u003eHeart.org\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6380\" data-end=\"6383\"\u003e\r\n\u003ch3 data-start=\"6385\" data-end=\"6405\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6406\" data-end=\"6971\"\u003e\u003cstrong data-start=\"6406\" data-end=\"6442\"\u003eVericiguat (marketed as Verquvo)\u003c\/strong\u003e is an important advancement in the management of chronic heart failure with reduced ejection fraction. By stimulating soluble guanylate cyclase and increasing cGMP levels, vericiguat promotes vasodilation and improves cardiac output, thereby reducing the risk of hospitalization and cardiovascular death. Due to its potential to lower blood pressure and its contraindications with certain agents (such as nitrates and PDE5 inhibitors), vericiguat must be used with careful monitoring under the guidance of a healthcare provider.\u003c\/p\u003e\r\n\u003cp data-start=\"6973\" data-end=\"7197\"\u003e\u003cem data-start=\"6973\" data-end=\"7197\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"Magento","offers":[{"title":"2.5 mg","offer_id":49210175389942,"sku":"Verquvo- 2.5 mg-1","price":43.14,"currency_code":"USD","in_stock":true},{"title":"false","offer_id":49210175422710,"sku":"Verquvo-5mg-1","price":67.2,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":49210175455478,"sku":"Verquvo-10mg-1","price":78.3,"currency_code":"USD","in_stock":true}]},{"product_id":"verquvo-5mg","title":"Verquvo-5mg","description":"\u003cdiv class=\"flex-1 overflow-hidden @container\/thread translate-y-[2rem] -mt-[2rem] pb-[1.5rem]\"\u003e\r\n\u003cdiv class=\"flex h-full flex-col overflow-y-auto\"\u003e\r\n\u003cdiv class=\"flex flex-col text-sm md:pb-9\"\u003e\r\n\u003carticle class=\"w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-49\" data-scroll-anchor=\"true\"\u003e\r\n\u003cdiv class=\"m-auto text-base py-[18px] px-6\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn @xs\/thread:px-0 @sm\/thread:px-1.5 @md\/thread:px-4\"\u003e\r\n\u003cdiv class=\"flex-col gap-1 md:gap-3\"\u003e\r\n\u003cdiv class=\"flex max-w-full flex-col flex-grow\"\u003e\r\n\u003cdiv class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+\u0026amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"2d806202-b9ff-4755-979c-5e5c5601c787\" data-message-model-slug=\"o3-mini\"\u003e\r\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\"\u003e\r\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\r\n\u003ch3 data-start=\"358\" data-end=\"383\"\u003eWhat is Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"384\" data-end=\"868\"\u003e\u003cstrong data-start=\"384\" data-end=\"398\"\u003eVericiguat\u003c\/strong\u003e is an oral soluble guanylate cyclase (sGC) stimulator used in the management of chronic heart failure with reduced ejection fraction (HFrEF), particularly in patients who have recently experienced worsening heart failure events. It is marketed under the brand name \u003cstrong data-start=\"664\" data-end=\"675\"\u003eVerquvo\u003c\/strong\u003e and is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.\u003cbr data-start=\"770\" data-end=\"773\"\u003e\u003cem data-start=\"773\" data-end=\"868\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"785\" data-end=\"867\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"870\" data-end=\"873\"\u003e\r\n\u003ch3 data-start=\"875\" data-end=\"929\"\u003eWhat are the other popular names for Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"930\" data-end=\"1155\"\u003eVericiguat is primarily known by its brand name \u003cstrong data-start=\"978\" data-end=\"989\"\u003eVerquvo\u003c\/strong\u003e. In clinical and academic literature, it is also referred to by its generic name, vericiguat.\u003cbr data-start=\"1083\" data-end=\"1086\"\u003e\u003cem data-start=\"1086\" data-end=\"1155\"\u003eReference: \u003ca href=\"https:\/\/www.drugs.com\/\" target=\"_new\" rel=\"noopener\" data-start=\"1098\" data-end=\"1154\"\u003eDrugs.com: Vericiguat Overview\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1157\" data-end=\"1160\"\u003e\r\n\u003ch3 data-start=\"1162\" data-end=\"1214\"\u003eWhat is the drug classification of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1215\" data-end=\"1535\"\u003eVericiguat is classified as an \u003cstrong data-start=\"1246\" data-end=\"1297\"\u003eoral soluble guanylate cyclase (sGC) stimulator\u003c\/strong\u003e. It falls under the broader category of \u003cstrong data-start=\"1338\" data-end=\"1367\"\u003eheart failure medications\u003c\/strong\u003e and is specifically designated for use as an adjunct therapy in patients with chronic HFrEF.\u003cbr data-start=\"1460\" data-end=\"1463\"\u003e\u003cem data-start=\"1463\" data-end=\"1535\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"1475\" data-end=\"1534\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1537\" data-end=\"1540\"\u003e\r\n\u003ch3 data-start=\"1542\" data-end=\"1589\"\u003eWhat is the mode of action of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1590\" data-end=\"2149\"\u003eVericiguat works by both sensitizing soluble guanylate cyclase (sGC) to endogenous nitric oxide (NO) and directly stimulating sGC independent of NO. This dual mechanism leads to increased production of cyclic guanosine monophosphate (cGMP), which promotes vasodilation, reduces myocardial stress, and exerts anti‑remodeling effects on the heart. These actions collectively help reduce cardiac workload and improve cardiovascular outcomes in patients with HFrEF.\u003cbr data-start=\"2051\" data-end=\"2054\"\u003e\u003cem data-start=\"2054\" data-end=\"2149\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2066\" data-end=\"2148\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2151\" data-end=\"2154\"\u003e\r\n\u003ch3 data-start=\"2156\" data-end=\"2185\"\u003eHow is Vericiguat used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2186\" data-end=\"2693\"\u003eVericiguat is used as part of a comprehensive treatment plan for adult patients with chronic HFrEF who have had a recent episode of worsening heart failure (e.g., hospitalization or need for outpatient intravenous diuretics). It is prescribed in addition to standard heart failure therapy (such as beta‑blockers, ACE inhibitors, or ARBs) to further reduce the risk of adverse cardiovascular events.\u003cbr data-start=\"2584\" data-end=\"2587\"\u003e\u003cem data-start=\"2587\" data-end=\"2693\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2599\" data-end=\"2692\"\u003ePARADIGM-HF and VICTORIA Trials – NEJM\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2695\" data-end=\"2698\"\u003e\r\n\u003ch3 data-start=\"2700\" data-end=\"2771\"\u003eWhat is the recommended dosage and administration for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"2772\" data-end=\"3226\"\u003e\r\n\u003cli data-start=\"2772\" data-end=\"2972\"\u003e\n\u003cstrong data-start=\"2774\" data-end=\"2784\"\u003eDosage\u003c\/strong\u003e: The recommended starting dose is \u003cstrong data-start=\"2819\" data-end=\"2840\"\u003e2.5 mg once daily\u003c\/strong\u003e, which is gradually titrated upward (typically to 5 mg, then 10 mg, and ultimately 15 mg once daily) as tolerated by the patient.\u003c\/li\u003e\r\n\u003cli data-start=\"2973\" data-end=\"3226\"\u003e\n\u003cstrong data-start=\"2975\" data-end=\"2993\"\u003eAdministration\u003c\/strong\u003e: Vericiguat is taken orally in capsule form and may be taken with or without food. Consistent daily dosing is crucial for maintaining its therapeutic effect.\u003cbr data-start=\"3151\" data-end=\"3154\"\u003e\u003cem data-start=\"3154\" data-end=\"3226\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"3166\" data-end=\"3225\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3228\" data-end=\"3231\"\u003e\r\n\u003ch3 data-start=\"3233\" data-end=\"3296\"\u003eWhat prescribing information is important for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3297\" data-end=\"3896\"\u003e\r\n\u003cli data-start=\"3297\" data-end=\"3482\"\u003e\n\u003cstrong data-start=\"3299\" data-end=\"3314\"\u003eIndications\u003c\/strong\u003e: Vericiguat is indicated for patients with chronic heart failure with reduced ejection fraction (HFrEF) who have recently experienced worsening heart failure events.\u003c\/li\u003e\r\n\u003cli data-start=\"3483\" data-end=\"3689\"\u003e\n\u003cstrong data-start=\"3485\" data-end=\"3506\"\u003eContraindications\u003c\/strong\u003e: It is contraindicated in patients with a history of angioedema related to ACE inhibitor or ARB therapy and should not be coadministered with nitrates or other potent vasodilators.\u003c\/li\u003e\r\n\u003cli data-start=\"3690\" data-end=\"3896\"\u003e\n\u003cstrong data-start=\"3692\" data-end=\"3706\"\u003eMonitoring\u003c\/strong\u003e: Patients should have regular assessments of blood pressure, renal function, electrolytes, and signs of infection.\u003cbr data-start=\"3821\" data-end=\"3824\"\u003e\u003cem data-start=\"3824\" data-end=\"3896\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"3836\" data-end=\"3895\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3898\" data-end=\"3901\"\u003e\r\n\u003ch3 data-start=\"3903\" data-end=\"3988\"\u003eWhat safety information, warnings, and cautions are associated with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3989\" data-end=\"4940\"\u003e\r\n\u003cli data-start=\"3989\" data-end=\"4096\"\u003e\n\u003cstrong data-start=\"3991\" data-end=\"4014\"\u003eCommon Side Effects\u003c\/strong\u003e: These include hypotension, dizziness, anemia, and gastrointestinal discomfort.\u003c\/li\u003e\r\n\u003cli data-start=\"4097\" data-end=\"4940\"\u003e\n\u003cstrong data-start=\"4099\" data-end=\"4122\"\u003eWarnings \u0026amp; Cautions\u003c\/strong\u003e:\r\n\u003cul data-start=\"4128\" data-end=\"4940\"\u003e\r\n\u003cli data-start=\"4128\" data-end=\"4243\"\u003e\n\u003cstrong data-start=\"4130\" data-end=\"4145\"\u003eHypotension\u003c\/strong\u003e: Vericiguat can cause a significant drop in blood pressure, particularly during dose titration.\u003c\/li\u003e\r\n\u003cli data-start=\"4246\" data-end=\"4378\"\u003e\n\u003cstrong data-start=\"4248\" data-end=\"4266\"\u003eInfection Risk\u003c\/strong\u003e: Although not as immunosuppressive as some other agents, patients should be monitored for signs of infection.\u003c\/li\u003e\r\n\u003cli data-start=\"4381\" data-end=\"4650\"\u003e\n\u003cstrong data-start=\"4383\" data-end=\"4404\"\u003eDrug Interactions\u003c\/strong\u003e:\r\n\u003cul data-start=\"4412\" data-end=\"4650\"\u003e\r\n\u003cli data-start=\"4412\" data-end=\"4525\"\u003e\n\u003cstrong data-start=\"4414\" data-end=\"4446\"\u003eNitrates and PDE5 Inhibitors\u003c\/strong\u003e: Concomitant use is contraindicated due to the risk of profound hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"4530\" data-end=\"4650\"\u003e\n\u003cstrong data-start=\"4532\" data-end=\"4559\"\u003eOther Antihypertensives\u003c\/strong\u003e: Combined use may amplify blood pressure–lowering effects, requiring careful monitoring.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4653\" data-end=\"4940\"\u003e\n\u003cstrong data-start=\"4655\" data-end=\"4687\"\u003eRenal and Hepatic Impairment\u003c\/strong\u003e: Dose adjustments and frequent monitoring may be necessary in patients with impaired renal or hepatic function.\u003cbr data-start=\"4799\" data-end=\"4802\"\u003e\u003cem data-start=\"4802\" data-end=\"4940\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"4814\" data-end=\"4896\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e, \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"4898\" data-end=\"4939\"\u003eFDA Verquvo Label\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"4942\" data-end=\"4945\"\u003e\r\n\u003ch3 data-start=\"4947\" data-end=\"5024\"\u003eWhat additional drug interactions should be considered with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"5025\" data-end=\"5605\"\u003e\r\n\u003cli data-start=\"5025\" data-end=\"5203\"\u003e\n\u003cstrong data-start=\"5027\" data-end=\"5098\"\u003eNitrates and Phosphodiesterase Type 5 Inhibitors (e.g., sildenafil)\u003c\/strong\u003e: Their combined use with Vericiguat is contraindicated due to an increased risk of severe hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"5204\" data-end=\"5303\"\u003e\n\u003cstrong data-start=\"5206\" data-end=\"5239\"\u003eOther Antihypertensive Agents\u003c\/strong\u003e: Coadministration may result in additive hypotensive effects.\u003c\/li\u003e\r\n\u003cli data-start=\"5304\" data-end=\"5605\"\u003e\n\u003cstrong data-start=\"5306\" data-end=\"5334\"\u003eCYP450 Enzyme Modulators\u003c\/strong\u003e: Although Vericiguat is not predominantly metabolized by CYP enzymes, caution is advised when it is used with drugs that significantly alter blood pressure or fluid balance.\u003cbr data-start=\"5508\" data-end=\"5511\"\u003e\u003cem data-start=\"5511\" data-end=\"5605\"\u003eReference: \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5523\" data-end=\"5604\"\u003eClinical Pharmacology Reviews, ACR Guidelines\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"5607\" data-end=\"5610\"\u003e\r\n\u003ch3 data-start=\"5612\" data-end=\"5684\"\u003eWhere can I learn more about Vericiguat and its clinical evidence?\u003c\/h3\u003e\r\n\u003cp data-start=\"5685\" data-end=\"5803\"\u003eFor further details on clinical studies, dosing strategies, and safety monitoring, refer to the following resources:\u003c\/p\u003e\r\n\u003cul data-start=\"5804\" data-end=\"6171\"\u003e\r\n\u003cli data-start=\"5804\" data-end=\"5871\"\u003e\u003cstrong data-start=\"5806\" data-end=\"5869\"\u003e\u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5808\" data-end=\"5867\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5872\" data-end=\"5979\"\u003e\u003cstrong data-start=\"5874\" data-end=\"5977\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"5876\" data-end=\"5975\"\u003eArmstrong et al., NEJM 2020 – VICTORIA Trial\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5980\" data-end=\"6099\"\u003e\n\u003cstrong data-start=\"5982\" data-end=\"6028\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5984\" data-end=\"6026\"\u003ePubMed\u003c\/a\u003e\u003c\/strong\u003e for additional peer‑reviewed research on vericiguat in heart failure\u003c\/li\u003e\r\n\u003cli data-start=\"6100\" data-end=\"6171\"\u003e\u003cstrong data-start=\"6102\" data-end=\"6171\"\u003e\u003ca href=\"https:\/\/www.acc.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6104\" data-end=\"6169\"\u003eAmerican College of Cardiology Guidelines\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6173\" data-end=\"6176\"\u003e\r\n\u003ch3 data-start=\"6178\" data-end=\"6198\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6199\" data-end=\"7031\"\u003e\u003cstrong data-start=\"6199\" data-end=\"6223\"\u003eVericiguat (Verquvo)\u003c\/strong\u003e is an innovative, orally administered sGC stimulator that significantly improves outcomes in patients with chronic heart failure with reduced ejection fraction (HFrEF) who have experienced recent worsening heart failure events. By enhancing cGMP production, vericiguat promotes vasodilation and reduces cardiac stress, contributing to a decrease in cardiovascular events. However, due to its potent blood pressure–lowering effects and potential drug interactions (especially with nitrates and other vasodilators), it must be used with caution and under strict medical supervision.\u003cbr data-start=\"6804\" data-end=\"6807\"\u003e\u003cem data-start=\"6807\" data-end=\"7031\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"pr-2 lg:pr-0\"\u003e \u003c\/div\u003e\r\n\u003cdiv class=\"mt-3 w-full empty:hidden\"\u003e\r\n\u003cdiv class=\"text-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"absolute\"\u003e\r\n\u003cdiv class=\"flex items-center justify-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/article\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"md:pt-0 dark:border-white\/20 md:border-transparent md:dark:border-transparent w-full isolate has-[[data-has-thread-error]]:[box-shadow:var(--sharp-edge-bottom-shadow)] has-[[data-has-thread-error]]:pt-2\"\u003e\r\n\u003cdiv\u003e\r\n\u003cdiv class=\"m-auto text-base px-3 md:px-4 w-full md:px-5 lg:px-4 xl:px-5\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"flex justify-center empty:hidden\"\u003e \u003c\/div\u003e\r\n\u003cform class=\"w-full\" aria-haspopup=\"dialog\" aria-expanded=\"false\" aria-controls=\"radix-:r19a:\" data-state=\"closed\"\u003e\r\n\u003cdiv class=\"relative z-[1] flex h-full max-w-full flex-1 flex-col\"\u003e\r\n\u003cdiv class=\"absolute bottom-full left-0 right-0 z-20\"\u003e \u003c\/div\u003e\r\n\u003cdiv class=\"group relative z-[1] flex w-full items-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/form\u003e\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Magento","offers":[{"title":"Default Title","offer_id":49641977872630,"sku":"Verquvo-5mg","price":142.86,"currency_code":"USD","in_stock":true}]},{"product_id":"verquvo-5mg-1","title":"Verquvo-5mg","description":"\u003ch3 data-start=\"231\" data-end=\"256\"\u003eWhat is Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"257\" data-end=\"596\"\u003e\u003cstrong data-start=\"257\" data-end=\"271\"\u003eVericiguat\u003c\/strong\u003e is an oral medication used as an adjunct to standard therapy in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) who remain at high risk of cardiovascular death or heart failure hospitalization. It is designed to improve cardiac performance by enhancing the nitric oxide–sGC–cGMP pathway.\u003c\/p\u003e\r\n\u003cp data-start=\"598\" data-end=\"735\"\u003e\u003cem data-start=\"598\" data-end=\"735\"\u003eReference: U.S. Food and Drug Administration (FDA) vericiguat prescribing information; ClinicalTrials.gov (VICTORIA trial, NCT02861534)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"737\" data-end=\"740\"\u003e\r\n\u003ch3 data-start=\"742\" data-end=\"796\"\u003eWhat are the other popular names for Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"797\" data-end=\"955\"\u003eVericiguat is marketed under the brand name \u003cstrong data-start=\"841\" data-end=\"852\"\u003eVerquvo\u003c\/strong\u003e. In clinical practice and academic literature, it is also referred to by its generic name, vericiguat.\u003c\/p\u003e\r\n\u003cp data-start=\"957\" data-end=\"998\"\u003e\u003cem data-start=\"957\" data-end=\"998\"\u003eReference: U.S. FDA; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1000\" data-end=\"1003\"\u003e\r\n\u003ch3 data-start=\"1005\" data-end=\"1057\"\u003eWhat is the drug classification of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1058\" data-end=\"1263\"\u003eVericiguat is classified as an \u003cstrong data-start=\"1089\" data-end=\"1140\"\u003eoral soluble guanylate cyclase (sGC) stimulator\u003c\/strong\u003e. It falls under the therapeutic category of \u003cstrong data-start=\"1185\" data-end=\"1214\"\u003eheart failure medications\u003c\/strong\u003e, specifically indicated for patients with HFrEF.\u003c\/p\u003e\r\n\u003cp data-start=\"1265\" data-end=\"1368\"\u003e\u003cem data-start=\"1265\" data-end=\"1368\"\u003eReference: U.S. FDA; National Institutes of Health (NIH); American Heart Association (AHA) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1370\" data-end=\"1373\"\u003e\r\n\u003ch3 data-start=\"1375\" data-end=\"1422\"\u003eWhat is the mode of action of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1423\" data-end=\"1669\"\u003eVericiguat works by enhancing the sensitivity of soluble guanylate cyclase (sGC) to endogenous nitric oxide (NO) and by directly stimulating sGC. This dual mechanism increases the production of cyclic guanosine monophosphate (cGMP), leading to:\u003c\/p\u003e\r\n\u003cul data-start=\"1670\" data-end=\"2006\"\u003e\r\n\u003cli data-start=\"1670\" data-end=\"1747\"\u003e\n\u003cstrong data-start=\"1672\" data-end=\"1689\"\u003eVasodilation:\u003c\/strong\u003e Relaxation of vascular smooth muscle reduces afterload.\u003c\/li\u003e\r\n\u003cli data-start=\"1748\" data-end=\"1891\"\u003e\n\u003cstrong data-start=\"1750\" data-end=\"1782\"\u003eImproved Cardiac Efficiency:\u003c\/strong\u003e Lower resistance allows the heart to pump more effectively without significantly increasing oxygen demand.\u003c\/li\u003e\r\n\u003cli data-start=\"1892\" data-end=\"2006\"\u003e\n\u003cstrong data-start=\"1894\" data-end=\"1925\"\u003eReduced Cardiac Remodeling:\u003c\/strong\u003e Over time, these effects may help limit adverse structural changes in the heart.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2008\" data-end=\"2102\"\u003e\u003cem data-start=\"2008\" data-end=\"2102\"\u003eReference: New England Journal of Medicine (NEJM) – VICTORIA trial (NEJMoa1917589); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2104\" data-end=\"2107\"\u003e\r\n\u003ch3 data-start=\"2109\" data-end=\"2138\"\u003eHow is Vericiguat used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2139\" data-end=\"2432\"\u003eVericiguat is used as an adjunct to guideline‑directed medical therapy (GDMT) in patients with symptomatic chronic HFrEF. It is prescribed for patients who continue to experience symptoms despite treatment with beta‑blockers, ACE inhibitors or ARBs, and mineralocorticoid receptor antagonists.\u003c\/p\u003e\r\n\u003cp data-start=\"2434\" data-end=\"2527\"\u003e\u003cem data-start=\"2434\" data-end=\"2527\"\u003eReference: American Heart Association (AHA) guidelines; ClinicalTrials.gov (VICTORIA trial)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2529\" data-end=\"2532\"\u003e\r\n\u003ch3 data-start=\"2534\" data-end=\"2605\"\u003eWhat is the recommended dosage and administration for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"2606\" data-end=\"3062\"\u003e\r\n\u003cli data-start=\"2606\" data-end=\"2855\"\u003e\n\u003cstrong data-start=\"2608\" data-end=\"2619\"\u003eDosage:\u003c\/strong\u003e\r\n\u003cul data-start=\"2624\" data-end=\"2855\"\u003e\r\n\u003cli data-start=\"2624\" data-end=\"2855\"\u003eTreatment typically begins with a lower dose (for example, \u003cstrong data-start=\"2685\" data-end=\"2706\"\u003e2.5 mg once daily\u003c\/strong\u003e) with gradual up-titration to a target maintenance dose (commonly between 10 mg and 15 mg once daily) based on clinical response and tolerability.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"2856\" data-end=\"3062\"\u003e\n\u003cstrong data-start=\"2858\" data-end=\"2877\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2882\" data-end=\"3062\"\u003e\r\n\u003cli data-start=\"2882\" data-end=\"3062\"\u003eVericiguat is taken orally in capsule form. It may be taken with or without food, but consistent dosing at the same time each day is advised for maintaining steady plasma levels.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3064\" data-end=\"3170\"\u003e\u003cem data-start=\"3064\" data-end=\"3170\"\u003eReference: U.S. FDA vericiguat prescribing information; ClinicalTrials.gov (VICTORIA trial, NCT02861534)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3172\" data-end=\"3175\"\u003e\r\n\u003ch3 data-start=\"3177\" data-end=\"3240\"\u003eWhat prescribing information is important for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3241\" data-end=\"4071\"\u003e\r\n\u003cli data-start=\"3241\" data-end=\"3451\"\u003e\n\u003cstrong data-start=\"3243\" data-end=\"3259\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3264\" data-end=\"3451\"\u003e\r\n\u003cli data-start=\"3264\" data-end=\"3451\"\u003eVericiguat is indicated to reduce the risk of cardiovascular death and heart failure hospitalization in patients with chronic HFrEF who are at high risk despite optimal medical therapy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3452\" data-end=\"3742\"\u003e\n\u003cstrong data-start=\"3454\" data-end=\"3476\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3481\" data-end=\"3742\"\u003e\r\n\u003cli data-start=\"3481\" data-end=\"3597\"\u003eIt is contraindicated in patients with a known hypersensitivity to vericiguat or any component of the formulation.\u003c\/li\u003e\r\n\u003cli data-start=\"3600\" data-end=\"3742\"\u003eConcomitant use with nitrates or potent phosphodiesterase type 5 (PDE5) inhibitors is contraindicated due to the risk of severe hypotension.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3743\" data-end=\"3865\"\u003e\n\u003cstrong data-start=\"3745\" data-end=\"3760\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3765\" data-end=\"3865\"\u003e\r\n\u003cli data-start=\"3765\" data-end=\"3865\"\u003ePatients should be regularly monitored for blood pressure, renal function, and serum electrolytes.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3866\" data-end=\"4071\"\u003e\n\u003cstrong data-start=\"3868\" data-end=\"3895\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3900\" data-end=\"4071\"\u003e\r\n\u003cli data-start=\"3900\" data-end=\"4071\"\u003eVericiguat is not recommended during pregnancy. Women of childbearing potential must use effective contraception during treatment and for a period after discontinuation.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4073\" data-end=\"4199\"\u003e\u003cem data-start=\"4073\" data-end=\"4199\"\u003eReference: U.S. Food and Drug Administration (FDA) vericiguat label; National Institutes of Health (NIH) clinical guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4201\" data-end=\"4204\"\u003e\r\n\u003ch3 data-start=\"4206\" data-end=\"4291\"\u003eWhat safety information, warnings, and cautions are associated with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"4292\" data-end=\"5016\"\u003e\r\n\u003cli data-start=\"4292\" data-end=\"4370\"\u003e\n\u003cstrong data-start=\"4294\" data-end=\"4318\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4323\" data-end=\"4370\"\u003e\r\n\u003cli data-start=\"4323\" data-end=\"4370\"\u003eHypotension, dizziness, headache, and anemia.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4371\" data-end=\"5016\"\u003e\n\u003cstrong data-start=\"4373\" data-end=\"4397\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4402\" data-end=\"5016\"\u003e\r\n\u003cli data-start=\"4402\" data-end=\"4566\"\u003e\n\u003cstrong data-start=\"4404\" data-end=\"4420\"\u003eHypotension:\u003c\/strong\u003e Patients are at risk for low blood pressure, especially during dose titration. Advise slow position changes and monitor blood pressure closely.\u003c\/li\u003e\r\n\u003cli data-start=\"4569\" data-end=\"4632\"\u003e\n\u003cstrong data-start=\"4571\" data-end=\"4586\"\u003eFetal Harm:\u003c\/strong\u003e Vericiguat is contraindicated in pregnancy.\u003c\/li\u003e\r\n\u003cli data-start=\"4635\" data-end=\"4858\"\u003e\n\u003cstrong data-start=\"4637\" data-end=\"4659\"\u003eDrug Interactions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4666\" data-end=\"4858\"\u003e\r\n\u003cli data-start=\"4666\" data-end=\"4750\"\u003eConcomitant use with nitrates or PDE5 inhibitors may lead to severe hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"4755\" data-end=\"4858\"\u003eCoadministration with other antihypertensives may result in additive blood pressure–lowering effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4861\" data-end=\"5016\"\u003e\n\u003cstrong data-start=\"4863\" data-end=\"4882\"\u003eOrgan Function:\u003c\/strong\u003e Caution is advised in patients with impaired renal or hepatic function; these patients require dose adjustments and close monitoring.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5018\" data-end=\"5141\"\u003e\u003cem data-start=\"5018\" data-end=\"5141\"\u003eReference: U.S. FDA; New England Journal of Medicine (NEJM) – VICTORIA trial; American Heart Association (AHA) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5143\" data-end=\"5146\"\u003e\r\n\u003ch3 data-start=\"5148\" data-end=\"5214\"\u003eWhat drug interactions should be considered with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"5215\" data-end=\"5679\"\u003e\r\n\u003cli data-start=\"5215\" data-end=\"5383\"\u003e\n\u003cstrong data-start=\"5217\" data-end=\"5280\"\u003eNitrates and PDE5 Inhibitors (e.g., Sildenafil, Tadalafil):\u003c\/strong\u003e\r\n\u003cul data-start=\"5285\" data-end=\"5383\"\u003e\r\n\u003cli data-start=\"5285\" data-end=\"5383\"\u003eThese are contraindicated when used with vericiguat because of the risk of profound hypotension.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5384\" data-end=\"5521\"\u003e\n\u003cstrong data-start=\"5386\" data-end=\"5420\"\u003eOther Antihypertensive Agents:\u003c\/strong\u003e\r\n\u003cul data-start=\"5425\" data-end=\"5521\"\u003e\r\n\u003cli data-start=\"5425\" data-end=\"5521\"\u003eConcurrent use may enhance blood pressure–lowering effects and necessitate dosage adjustments.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5522\" data-end=\"5679\"\u003e\n\u003cstrong data-start=\"5524\" data-end=\"5560\"\u003eAgents Affecting Renal Function:\u003c\/strong\u003e\r\n\u003cul data-start=\"5565\" data-end=\"5679\"\u003e\r\n\u003cli data-start=\"5565\" data-end=\"5679\"\u003eDrugs that impair renal hemodynamics may affect the pharmacokinetics of vericiguat; close monitoring is advised.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5681\" data-end=\"5760\"\u003e\u003cem data-start=\"5681\" data-end=\"5760\"\u003eReference: U.S. FDA vericiguat label; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5762\" data-end=\"5765\"\u003e\r\n\u003ch3 data-start=\"5767\" data-end=\"5861\"\u003eWhere can I find additional clinical evidence and detailed information about Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"5862\" data-end=\"5956\"\u003eFor further details on clinical studies, dosing guidelines, and safety monitoring, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"5957\" data-end=\"6378\"\u003e\r\n\u003cli data-start=\"5957\" data-end=\"6045\"\u003e\n\u003cstrong data-start=\"5959\" data-end=\"6011\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6012\" data-end=\"6043\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6046\" data-end=\"6154\"\u003e\n\u003cstrong data-start=\"6048\" data-end=\"6102\"\u003eClinicalTrials.gov – VICTORIA Trial (NCT02861534):\u003c\/strong\u003e \u003ca href=\"https:\/\/clinicaltrials.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6103\" data-end=\"6152\"\u003eClinicalTrials.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6155\" data-end=\"6291\"\u003e\n\u003cstrong data-start=\"6157\" data-end=\"6229\"\u003eNew England Journal of Medicine (NEJM) – VICTORIA Trial Publication:\u003c\/strong\u003e \u003ca target=\"_new\" rel=\"noopener\" data-start=\"6230\" data-end=\"6289\"\u003eNEJM\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6292\" data-end=\"6378\"\u003e\n\u003cstrong data-start=\"6294\" data-end=\"6342\"\u003eAmerican Heart Association (AHA) Guidelines:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.heart.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6343\" data-end=\"6378\"\u003eHeart.org\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6380\" data-end=\"6383\"\u003e\r\n\u003ch3 data-start=\"6385\" data-end=\"6405\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6406\" data-end=\"6971\"\u003e\u003cstrong data-start=\"6406\" data-end=\"6442\"\u003eVericiguat (marketed as Verquvo)\u003c\/strong\u003e is an important advancement in the management of chronic heart failure with reduced ejection fraction. By stimulating soluble guanylate cyclase and increasing cGMP levels, vericiguat promotes vasodilation and improves cardiac output, thereby reducing the risk of hospitalization and cardiovascular death. Due to its potential to lower blood pressure and its contraindications with certain agents (such as nitrates and PDE5 inhibitors), vericiguat must be used with careful monitoring under the guidance of a healthcare provider.\u003c\/p\u003e\r\n\u003cp data-start=\"6973\" data-end=\"7197\"\u003e\u003cem data-start=\"6973\" data-end=\"7197\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"Magento","offers":[{"title":"Default Title","offer_id":49642184179958,"sku":"Verquvo-5mg-1","price":67.2,"currency_code":"USD","in_stock":true}]}],"url":"https:\/\/chemistway.com\/collections\/verquvo.oembed","provider":"Chemistway","version":"1.0","type":"link"}